Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Target Disease Indication, By Neoantigens Type, By Immunotherapy Type, By Route of Administration, By Region & Competition, 2021-2031F

Description

The Global Neoantigen Targeted Therapies Market is projected for substantial growth, anticipating an increase from USD 1.99 Billion in 2025 to USD 3.23 Billion by 2031, at an 8.41% Compound Annual Growth Rate. These immunotherapeutic agents are specifically engineered to identify and eliminate tumor-specific antigens derived from DNA mutations, thereby directing the immune system precisely against cancer cells. The market's expansion is fundamentally driven by the escalating global incidence of malignancies and the urgent clinical necessity for treatment regimens that minimize off-target toxicity, ultimately aiming to enhance long-term survival through heightened specificity in oncology treatment. However, the widespread adoption of these therapies is significantly challenged by the intricate and capital-intensive manufacturing processes required for individual patient formulations. This logistical impediment complicates the industry's capacity to meet the substantial demand indicated by recent health statistics; for instance, the American Cancer Society projected approximately 2,041,910 new cancer cases in the United States for 2025. Therefore, establishing scalable and cost-efficient production models remains a critical obstacle impeding the broader commercial expansion of this sector.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 1.99 Billion
Market Size 2031	USD 3.23 Billion
CAGR 2026-2031	8.41%
Fastest Growing Segment	Off-the-Shelf Neoantigens
Largest Market	North America

Market Driver

The integration of bioinformatics and artificial intelligence serves as a primary catalyst for the market, enabling the precise identification of tumor-specific mutations from vast next-generation sequencing datasets. This technological convergence empowers developers to select neoantigens with the highest immunogenicity, thereby significantly enhancing the clinical efficacy of personalized vaccines compared to non-specific immunotherapies. The clinical viability of this approach was recently substantiated by positive trial outcomes; Moderna reported in June 2024 that its investigational neoantigen therapy mRNA-4157, when combined with pembrolizumab, reduced the risk of recurrence or death by 49% in high-risk melanoma patients compared to monotherapy, confirming the maturation of computational prediction algorithms into viable therapeutic tools. Simultaneously, the expansion of strategic partnerships and research investments is accelerating the transition of these therapies from experimental stages to commercial pipelines. Pharmaceutical entities are substantially funding mRNA and vector-based delivery platforms to overcome manufacturing bottlenecks and support late-stage trials; BioNTech, for example, projected a research and development spend of up to €2.6 billion for the 2024 financial year to advance its oncology portfolio, as stated in March 2024. This influx of capital is critical, given that the International Agency for Research on Cancer projected in 2024 that the global cancer burden is expected to rise to 35 million new cases by 2050, underscoring the immense addressable market for scalable neoantigen solutions.

Market Challenge

The principal challenging factor is the intricate and capital-intensive manufacturing process necessary for individual patient formulations, which acts as a direct impediment to the growth of the Global Neoantigen Targeted Therapies Market by preventing the scalability essential to meet global demand. Unlike 'off-the-shelf' pharmaceuticals, these personalized immunotherapies necessitate a unique production cycle for every patient, thereby eliminating standard economies of scale and resulting in prohibitively high costs of goods sold. Consequently, manufacturers encounter severe constraints in expanding production capacity to match the rising prevalence of malignancies, which limits both market penetration and patient access. The impact of these manufacturing hurdles is evident in the difficulty companies face when transitioning from clinical development to broad commercial success. The high complexity of producing personalized treatments creates a bottleneck, allowing only a few therapies to reach a substantial volume of patients. This struggle for scalability is reflected in recent industry data: according to the Alliance for Regenerative Medicine, approximately 75 percent of the global revenue in the advanced therapy sector in 2025 was generated by fewer than 10 products, highlighting the significant friction that manufacturing limitations impose on the broader commercial expansion of personalized oncology regimens.

Market Trends

The emergence of off-the-shelf shared neoantigen therapies represents a key trend addressing the critical scalability limits inherent in personalized manufacturing. By targeting common driver mutations, such as KRAS, that appear across specific patient populations, these ready-to-use formulations eliminate the lengthy production cycles typically required for bespoke vaccines, thus enabling immediate patient access. This streamlined model is beginning to generate substantial clinical evidence, proving that standardizing target selection can yield therapeutic benefits comparable to fully individualized regimens; Elicio Therapeutics, for instance, reported in December 2024 that its off-the-shelf candidate ELI-002 achieved a median recurrence-free survival of 16.3 months in patients with resected KRAS-mutant solid tumors, validating the efficacy of this shared-antigen approach. Concurrently, clinical development is pivoting toward adjuvant and early-stage settings, moving beyond the historical reliance on metastatic salvage lines. This strategic shift aims to eradicate minimal residual disease by deploying neoantigen vaccines when the patient's immune system is most robust and the tumor burden is minimal, significantly increasing the likelihood of preventing relapse. This approach is yielding durable remission data in aggressive indications where standard treatments often fail, as demonstrated by BioNTech's April 2024 data, which showed that adjuvant autogene cevumeran in resected pancreatic cancer resulted in a median recurrence-free survival that was not reached in immune responders, significantly outperforming the 13.4 months observed in non-responders.

Key Market Players

BioNtech SE
Gritstone Bio, Inc.
Genocea Biosciences Inc.
Moderna Inc.
Agenus Inc.
Immatics NV
Advaxis Inc
Precision Biologics
Gilead Sciences, Inc.
Cellular Biomedicine Group Inc.
Achillies Therapeutics Plc.
Merck & Co Inc.

Report Scope

In this report, the Global Neoantigen Targeted Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neoantigen Targeted Therapies Market, By Target Disease Indication

Bone Cancer
Colorectal Cancer
Gynecological Cancer
Non-Small Cell Lung Cancer
Renal Cell Carcinoma

Neoantigen Targeted Therapies Market, By Neoantigens Type

Off-the-Shelf Neoantigens
Personalized Neoantigens

Neoantigen Targeted Therapies Market, By Immunotherapy Type

Dendritic Cell Vaccines
DNA / RNA-Based Vaccines
Protein / Peptide-based Vaccines
TIL-Based Therapies

Neoantigen Targeted Therapies Market, By Route of Administration

Intradermal
Intravenous
Subcutaneous

Neoantigen Targeted Therapies Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Targeted Therapies Market.

Available Customizations:

Global Neoantigen Targeted Therapies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neoantigen Targeted Therapies Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma)
- 5.2.2. By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens)
- 5.2.3. By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies)
- 5.2.4. By Route of Administration (Intradermal, Intravenous, Subcutaneous)
- 5.2.5. By Region
- 5.2.6. By Company (2025)
5.3. Market Map

6. North America Neoantigen Targeted Therapies Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Target Disease Indication
- 6.2.2. By Neoantigens Type
- 6.2.3. By Immunotherapy Type
- 6.2.4. By Route of Administration
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Neoantigen Targeted Therapies Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Target Disease Indication
    - 6.3.1.2.2. By Neoantigens Type
    - 6.3.1.2.3. By Immunotherapy Type
    - 6.3.1.2.4. By Route of Administration
- 6.3.2. Canada Neoantigen Targeted Therapies Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Target Disease Indication
    - 6.3.2.2.2. By Neoantigens Type
    - 6.3.2.2.3. By Immunotherapy Type
    - 6.3.2.2.4. By Route of Administration
- 6.3.3. Mexico Neoantigen Targeted Therapies Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Target Disease Indication
    - 6.3.3.2.2. By Neoantigens Type
    - 6.3.3.2.3. By Immunotherapy Type
    - 6.3.3.2.4. By Route of Administration

7. Europe Neoantigen Targeted Therapies Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Target Disease Indication
- 7.2.2. By Neoantigens Type
- 7.2.3. By Immunotherapy Type
- 7.2.4. By Route of Administration
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Neoantigen Targeted Therapies Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Target Disease Indication
    - 7.3.1.2.2. By Neoantigens Type
    - 7.3.1.2.3. By Immunotherapy Type
    - 7.3.1.2.4. By Route of Administration
- 7.3.2. France Neoantigen Targeted Therapies Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Target Disease Indication
    - 7.3.2.2.2. By Neoantigens Type
    - 7.3.2.2.3. By Immunotherapy Type
    - 7.3.2.2.4. By Route of Administration
- 7.3.3. United Kingdom Neoantigen Targeted Therapies Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Target Disease Indication
    - 7.3.3.2.2. By Neoantigens Type
    - 7.3.3.2.3. By Immunotherapy Type
    - 7.3.3.2.4. By Route of Administration
- 7.3.4. Italy Neoantigen Targeted Therapies Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Target Disease Indication
    - 7.3.4.2.2. By Neoantigens Type
    - 7.3.4.2.3. By Immunotherapy Type
    - 7.3.4.2.4. By Route of Administration
- 7.3.5. Spain Neoantigen Targeted Therapies Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Target Disease Indication
    - 7.3.5.2.2. By Neoantigens Type
    - 7.3.5.2.3. By Immunotherapy Type
    - 7.3.5.2.4. By Route of Administration

8. Asia Pacific Neoantigen Targeted Therapies Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Target Disease Indication
- 8.2.2. By Neoantigens Type
- 8.2.3. By Immunotherapy Type
- 8.2.4. By Route of Administration
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Neoantigen Targeted Therapies Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Target Disease Indication
    - 8.3.1.2.2. By Neoantigens Type
    - 8.3.1.2.3. By Immunotherapy Type
    - 8.3.1.2.4. By Route of Administration
- 8.3.2. India Neoantigen Targeted Therapies Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Target Disease Indication
    - 8.3.2.2.2. By Neoantigens Type
    - 8.3.2.2.3. By Immunotherapy Type
    - 8.3.2.2.4. By Route of Administration
- 8.3.3. Japan Neoantigen Targeted Therapies Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Target Disease Indication
    - 8.3.3.2.2. By Neoantigens Type
    - 8.3.3.2.3. By Immunotherapy Type
    - 8.3.3.2.4. By Route of Administration
- 8.3.4. South Korea Neoantigen Targeted Therapies Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Target Disease Indication
    - 8.3.4.2.2. By Neoantigens Type
    - 8.3.4.2.3. By Immunotherapy Type
    - 8.3.4.2.4. By Route of Administration
- 8.3.5. Australia Neoantigen Targeted Therapies Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Target Disease Indication
    - 8.3.5.2.2. By Neoantigens Type
    - 8.3.5.2.3. By Immunotherapy Type
    - 8.3.5.2.4. By Route of Administration

9. Middle East & Africa Neoantigen Targeted Therapies Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Target Disease Indication
- 9.2.2. By Neoantigens Type
- 9.2.3. By Immunotherapy Type
- 9.2.4. By Route of Administration
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Neoantigen Targeted Therapies Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Target Disease Indication
    - 9.3.1.2.2. By Neoantigens Type
    - 9.3.1.2.3. By Immunotherapy Type
    - 9.3.1.2.4. By Route of Administration
- 9.3.2. UAE Neoantigen Targeted Therapies Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Target Disease Indication
    - 9.3.2.2.2. By Neoantigens Type
    - 9.3.2.2.3. By Immunotherapy Type
    - 9.3.2.2.4. By Route of Administration
- 9.3.3. South Africa Neoantigen Targeted Therapies Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Target Disease Indication
    - 9.3.3.2.2. By Neoantigens Type
    - 9.3.3.2.3. By Immunotherapy Type
    - 9.3.3.2.4. By Route of Administration

10. South America Neoantigen Targeted Therapies Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Target Disease Indication
- 10.2.2. By Neoantigens Type
- 10.2.3. By Immunotherapy Type
- 10.2.4. By Route of Administration
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Neoantigen Targeted Therapies Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Target Disease Indication
    - 10.3.1.2.2. By Neoantigens Type
    - 10.3.1.2.3. By Immunotherapy Type
    - 10.3.1.2.4. By Route of Administration
- 10.3.2. Colombia Neoantigen Targeted Therapies Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Target Disease Indication
    - 10.3.2.2.2. By Neoantigens Type
    - 10.3.2.2.3. By Immunotherapy Type
    - 10.3.2.2.4. By Route of Administration
- 10.3.3. Argentina Neoantigen Targeted Therapies Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Target Disease Indication
    - 10.3.3.2.2. By Neoantigens Type
    - 10.3.3.2.3. By Immunotherapy Type
    - 10.3.3.2.4. By Route of Administration

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Neoantigen Targeted Therapies Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. BioNtech SE
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Gritstone Bio, Inc.
15.3. Genocea Biosciences Inc.
15.4. Moderna Inc.
15.5. Agenus Inc.
15.6. Immatics NV
15.7. Advaxis Inc
15.8. Precision Biologics
15.9. Gilead Sciences, Inc.
15.10. Cellular Biomedicine Group Inc.
15.11. Achillies Therapeutics Plc.
15.12. Merck & Co Inc.